Quality issue at Baltimore vaccine plant delays some of Johnson & Johnson's vaccineThe FDA's inspection of Emergent's Bayview facility in Baltimore ended Tuesday and a newly released document details issues that could affect quality during manufacturing -- including incomplete investigations into cross-contamination, written procedures that weren't followed, poorly maintained facilities and a lack of employee training. New production was halted at the FDA's request, Dr.
Emergent's situation likely won't influence or push back any decisions around possibly resuming Johnson & Johnson vaccinations moving forward, Dr. Anthony Fauci, chief medical adviser to President Biden, told CNN's Victor Blackwell on Wednesday.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CNBC - 🏆 12. / 72 Read more »